

## ORIGINAL ARTICLE

# T594M mutation of the epithelial sodium channel beta subunit: No association with essential hypertension in Sudanese hypertensive

Huda A Fadlalmula<sup>1</sup>, Elsadig E Elmahdi<sup>2</sup>, Manal A Fadl<sup>3</sup>

<sup>1</sup>Dept. of Epidemiology, Tropical Medicine Research Institute, National Centre for Research Khartoum, Sudan

<sup>2</sup>University of Bahry, Faculty of Medicine, Khartoum, Sudan

<sup>3</sup>AlNeelain University, Faculty of Science and Technology, Khartoum, Sudan

## ABSTRACT

**Background** Hypertension is a multi-factorial disease, results from interplay between genetic and environmental factors. The epithelial sodium channel gene (*SCNN1 $\beta$* ) was known to regulate sodium absorption in the distal renal tubule. The T594M mutation of this gene results in an excess sodium reabsorption leading to high blood pressure. This study aimed to demonstrate a possible association between T594M C/T mutation of the *SCNN1 $\beta$*  (rs1799979) with essential hypertension in our population.

**Method** 179 hypertensive and 100 normotensives were enrolled in this study. T594M mutation was detected by RFLP-PCR using *Nla*III restriction enzyme.

**Results** T594M mutation was found to be non-polymorphic.; both hypertensive and normotensives have the CC wild-type pattern and only one hypertensive carries the mutant heterozygote CT. A significant gender difference was observed with three folds of females increased risk (OR=2.79); 92% of the cases were above 40 years old, with significant difference when compared to the controls ( $p = 0.01$ ); 41.3% and 26% of the hypertensives developed diabetes and hyperlipidaemia, respectively.

**Conclusion** This study did not show any association between the T594M mutation of the *SCNN1 $\beta$*  gene with essential hypertension in the examined subjects, but also showed the rarity of the T594M mutation in our population.

\*Correspondence to manalfadl1@hotmail.com.

## INTRODUCTION

Hypertension is one of the primary risk factors for cardiovascular diseases and the leading causes of death worldwide<sup>1</sup>. The incidence of hypertension continues to accelerate globally. It is known to affect over a billion people worldwide, causing disability and death to over 10 million all over the globe<sup>2,3</sup>. With the adoption of new westernized lifestyle, coupled with an in adequate and/or insufficient disease control; the developing countries, including Sudan, have received the highest burden of hypertension<sup>4</sup>. Hypertension is a multifactorial disease. It occurs as a result of a complex interplay of environmental risk factors with multiple genetic

factors. Although the non-genetic, behavioral risks are important risk factors for hypertension, the genetic factor is the most important one; it gives an insight to the mechanism of the disease and paves the road for better control, prevention and treatment<sup>5</sup>. The previous linkage or association studies have documented the role of certain candidate genes with hypertension predisposition. Of these genes are the renin angiotensin aldosterone system, NEJD protein and epithelial sodium channel<sup>6,7</sup>.

Resistant hypertension is a global issue with only 33% of hypertensive adults had controlled blood

pressure<sup>8</sup>. The resistance is due to medication non adherence, medication cost and patient genotype<sup>9</sup>. Africans were found to excrete less sodium than their white counterparts; this is explained by the differences of their genetic components<sup>10</sup>. This phenomenon is known as salt sensitive hypertension which is a common phenotype in black people<sup>10</sup>. It is explained by sodium reabsorption in the kidney; thereby several previous studies have focused on the role of the kidneys in hypertension<sup>11</sup>. The epithelial sodium channel was known to play critical role in this phenotype as it has very important role in maintaining sodium balance<sup>12</sup>. Moreover, drug target for reducing blood pressure among hypertensive; gave it the name amiloride sensitive sodium channel<sup>13</sup>. Four subunits;  $\alpha$ ,  $\beta$ ,  $\gamma$ , and  $\delta$  of epithelial sodium channel were previously discovered<sup>14,15</sup>. Several mutations in channel subunits were associated with an inherited form of hypertension<sup>16,17</sup>. Of these mutations is the T594M (C/T) missense single nucleotide mutation in  $\beta$  subunit of the last exon (exon 13 of the sodium-channel of Chromosome 16); which leads to the substitution of threonine [ACG] by methionine [ATG]) at amino acid 594, causes the synthesis of a protein with an altered amino acid sequence<sup>18</sup>. The subunit of the sodium-channel is a potential target site for phosphorylation by protein kinase C (PKC) which down-regulates sodium channels. The T594M variant was known to increase sodium channel activity in the distal renal tubule by making the channels to become insensitive to negative regulation by PKC, which leads to an excess tubular sodium reabsorption leading to high blood pressure<sup>19</sup>. The  $\beta$ -T594M mutation of the sodium channel was found in people with hypertension of African descent, and it is suspected to play role in salt sensitivity phenotype, however, the results were partly conflicting<sup>17-19</sup>.

In Sudan, to the best of our knowledge, there was only one genetic study of hypertension targeting the association of Nitric Oxide Synthase 3 with hypertension<sup>20</sup>. Given the fact that hypertension is a polygenic disease; this reflects an increasing need to understand the underlying genetic mechanisms

of the disease. Therefore, this study aimed to demonstrate a possible association of the T594M of the sodium channel (rs1799979) with essential hypertension among the genetically diverse Sudanese population.

## METHODS

This is a cross sectional hospital based study, conducted to assess the prevalence of the genetic variant of sodium channel  $\beta$  subunit (T594M mutation) (rs1799979), and to determine a possible co-occurrence of this mutation with essential hypertension in Sudanese population. Patients with essential hypertension and normotensive of ages ranging from 20-80 years are included. The newly diagnosed patients and the normotensive controls have been confirmed with or without hypertension by an expert physician; according to the criteria of the International Society of Hypertension [systolic blood pressure (SBP)  $\geq$  140 mmHg or diastolic blood pressure (DBP)  $\geq$  90 mmHg]. Patients with hypertension secondary to other diseases such as diabetes were excluded.

A total of 179 of the confirmed hypertensive patients and 100 normotensive control samples were included in this study. Verbal consent was obtained from each participant prior to enrollment and after explaining the purpose of the study. The demographic data was obtained using a well-designed questionnaire. 3 ml of venous blood sample from both cases and controls were collected in EDTA container, blood was centrifuged and plasma aspirated into another container.

## DNA extraction

Genomic DNA was extracted using guanidine chloride extraction method and the extracted DNA was stored at -20° C until used. Nanodrop photometry was used to test the quantity and the quality of the extracted DNA. Amplification of the sequence containing the T594M mutation of the sodium channel was done using the primer sequences as follow: Sense primer 5'-TCGACTTTGTGTGGATCACC -3'. Antisense primer 5'- GCATCACCCCTCACTGTCAGA -3'.

The PCR was conducted using master mix ready to use from iNtRON Biotechnology Company, Inc. following the manufacture instructions with final volume 20  $\mu$ l. PCR programmed to amplify the target sequence as follow: initial denaturation at 95°C for 2min. 35 cycles of denaturation at 94°C for 30 sec, followed by annealing at 59°C for 30 sec, then extension at 72°C for 30 sec. Final extension at 72°C for 5 min, followed by storing temperature at 4°C for 5 min.

### Restriction fragment length polymorphism

The Biolab. Digest® Nla III restriction enzyme recognizes the 5'.....CATG.....3'

Three microlitres of the PCR product was added to 2U of NlaIII restriction enzyme and one  $\mu$ l of digestion buffer and the volume was completed to 20  $\mu$ l, incubated for overnight at 37°C. The mixture was then loaded into 2% agarose gel, electrophoresed and the result visualized in a gel documentation system. The genotypes were scored as follows: The presence of one band sized 283 base pair (bp) indicates a homozygous wild type, three bands (283-149-134) in case of heterozygous, and two bands (149,134) in case of homozygous mutant.

Statistical analysis was done using the statistical package for social sciences (SPSS) software version 21. P-value < 0.05 was taken as significant. Odds

ratio (OR) with 95% confidence interval (CI) was used to assess the strength of the association.

## RESULTS

The study included 179 hypertensive patients and 100 normotensive controls. The age of hypertensive patients ranged from 20 to 80 years, and that of controls ranged from 20 to 90 years; 92% of the cases were aged more than 40 years with significant difference when compared to the controls ( $p = 0.01$ ), this age group has a 2.5-fold increased risk of hypertension. A significant gender difference was observed with three-fold increase of females ( $P=0.001$ , OR=2.79). Large scale of the hypertensives within less than ten years of disease duration, they developed diabetes (41.3%) and hyperlipidaemia (26.2%), with less frequency of stroke (5.1%) and kidney disease (3.9%) (Table 1).

The genotypes of the T594M mutation of the sodium channel was shown in Figures 2 and 3. The CC wild-type genotype was frequently observed among both cases and controls (99.4% and 100%, respectively). The CT genotype was observed in only one hypertensive patient (Table 2). The difference between the two groups was not statistically significant.

**Table 1.** The demographic data of the hypertensive cases (n=179)

compared to the normotensives (n=100)


Parameter	Case	Control	P-value
	N (%)	N (%)	
Age	<40 years	14 (7.8)	18 (18)
	>40 years	165 (92.2)	82 (82)
Sex	Male	53 (29.6)	54(54)
	Female	126 (70.4)	46(46)
Diabetes mellitus	Yes	74 (41.3)	
	No	105 (58.7)	
Stroke	Yes	9 (5.1)	
	No	169 (94.9)	
Kidney disease	Yes	7(3.9)	
	No	172(96.1)	

Gout	Yes	9.6%
	No	90.4%
Hyperlipidaemia	Yes	26.2%
	No	73.8%
Duration		
Less than 10 years		78.5%
More than 10 years		12.5%


OR = Odds ratio

**Table 2.** Genotypes distribution of T594M mutation of the sodium channel in hypertensive patients (n=179) and normotensive controls (n=100).


Genotypes/alleles	Patients	Controls	P value
	n(%)	n (%)	
CC	178 (99.4)	100 (100)	P= 0.64
CT	1 (0.6)	0	
TT	0	0	
C	0.997(99.7)	100 (100)	
T	0.003(0.3)	0	



**Figure 1.** The prevalence of complications of hypertension within ten years duration of the disease.



**Figure 2.** The T594M of SCCN $\beta$  gene amplicon. All lanes are PCR product with 283 base pair size, except lane 6 represent 100 base pair molecular DNA marker.



**Figure 3.** RFLP of T594M variant. All lanes were homozygote wild type allele samples (283 base pair (bp) except lane No 9 shows heterozygote allele (283, 149 and 134 bp) and lane 5 represent 100 bp DNA molecular marker.

## DISCUSSION

Hypertension “the silent killer” is a public health problem worldwide as it raises the risk of heart disease and can shorten people’s life expectancy<sup>21</sup>. The magnitude of hypertension continues to accelerate globally<sup>1,2</sup>. In Sudan, the prevalence of hypertension in Sudanese population rose from 7.5% in 1985 to 18.2% in 2002<sup>22</sup>. The complexity of the disease that involves an interaction of diverse environmental conditions with multiple genetic factors; has encouraged the research to identify the underlying genetic mechanisms of the disease<sup>23</sup>. Based on the fact that T594M sodium channel  $\beta$ -

subunit missense mutation may increase sodium-channel activity and could raise blood pressure in affected people by increasing renal tubular sodium reabsorption, this study was undertaken to determine the frequency of carriers of this mutation and to examine whether any relationship exists between this mutation and the susceptibility to hypertension.

The result revealed that T594M mutation of the *SCNN1β* (rs1799979) was found to be non-polymorphic. Only one of the 179 examined hypertensive has a mutation whereas none of the controls had the T594M mutation. Therefore, the finding of one case harboring one copy of the mutant allele of the T594M mutation did not give good insight about the association of mutation and hypertension in Sudanese, which is in agreement with study conducted in black hypertensive from South African, in Indian ethnic group and two studies in Japanese population<sup>24-27</sup>. On the other hand, this result is inconsistent with the finding of previous studies conducted in black people of African origin that suggest a possible role of the T594M variant to the susceptibility to high blood in African population<sup>28,29</sup>.

Despite the causal effect of this mutation as it changes the amino acid leading to excess tubular sodium reabsorption; however, the rarity and the lack of the association with hypertension in the examined subjects could be explained by:

1. The sodium channel might be affected by additional mutation/s within the *SCNN1β* gene which works in an integrated pattern to cause the disease.
2. The heterogeneity of the enrolled subjects, who are belonging to diverse ethnic groups, necessitates a large sample size to obtain a sufficient statistical power to detect genetic risk factors.

## CONCLUSIONS AND RECOMMENDATIONS

- o The T594M sodium channel β-subunit variant does not appear to play any significant contributory role in the susceptibility to hypertension in the examined subjects.

- o Hypertension is a polygenic disease with more than a single gene act in synergism to contribute to the disease warranted further investigation which will help develop patient-specific treatment.
- o Because of the heterogeneity of the examined subjects, this data could be considered as a pilot study that encourage us to focus later on a homogeneous ethnic group that has a relatively uniform genetic background or less complex, and expectedly sharing environmental and behavioral risks, thereby small sample size enabling to obtain a sufficient statistical power for the detection of genetic risks.

## Acknowledgements

We would like to thank all individuals who participated willingly in this study. Partial funding came from the Ministry of Higher Education.

## REFERENCES

1. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. *Lancet* 2005;365(9455):217-23.
2. Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. *Circulation* 2016;134(6):441-50.
3. Global, regional, and national comparative risk assessment of 84 behavioural, environmental and occupational, and metabolic risks or clusters of risks for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392(10159):1923-94.
4. Bushara SO, Noor SK, Elmadhoun WM, Sulaiman AA, Ahmed MH. Undiagnosed hypertension in a rural community in Sudan and association with some features of the metabolic

syndrome: how serious is the situation? *Renal Failure* 2015;37(6):1022-6.

5. Virdis A, Giannarelli C, Neves MF, Taddei S, Ghiadoni L. Cigarette smoking and hypertension. *Current Pharmaceutical Design* 2010;16(23):2518-25.
6. Jiang X, Sheng HH, Lin G, Li J, Lu XZ, Cheng YL, et al. Effect of renin-angiotensin-aldosterone system gene polymorphisms on blood pressure response to antihypertensive treatment. *Chinese Medical Journal* 2007;120(9):782-6.
7. Woodiwiss AJ, Nkeh B, Samani NJ, Badenhorst D, Maseko M, Tiago AD, et al. Functional variants of the angiotensinogen gene determine antihypertensive responses to angiotensin-converting enzyme inhibitors in subjects of African origin. *Journal of Hypertension* 2006;24(6):1057-64.
8. Thoenes M, Neuberger HR, Volpe M, Khan BV, Kirch W, Bohm M. Antihypertensive drug therapy and blood pressure control in men and women: an international perspective. *Journal of Human Hypertension* 2010;24(5):336-44.
9. Johnson JA. Advancing management of hypertension through pharmacogenomics. *Annals of Medicine* 2012;44 Suppl 1:S17-22.
10. Weinberger MH, Luft FC, Bloch R, Henry DP, Pratt JH, Weyman AE, et al. The blood pressure-raising effects of high dietary sodium intake: racial differences and the role of potassium. *Journal of the American College of Nutrition* 1982;1(2):139-48.
11. Shimosawa T, Mu S, Shibata S, Fujita T. The kidney and hypertension: pathogenesis of salt-sensitive hypertension. *Curr Hypertens Rep* 2012;14(5):468-72.
12. Lindhorst J, Alexander N, Blignaut J, Rayner B. Differences in hypertension between blacks and whites: an overview. *Cardiovascular Journal of Africa* 2007;18(4):241-7.
13. Swift PA, MacGregor GA. The epithelial sodium channel in hypertension: genetic heterogeneity and implications for treatment with amiloride. *American Journal of Pharmacogenomics Genomics-related Research in Drug Development and Clinical Practice* 2004;4(3):161-8.
14. Canessa CM, Schild L, Buell G, Thorens B, Gautschi I, Horisberger JD, et al. Amiloride-sensitive epithelial Na<sup>+</sup> channel is made of three homologous subunits. *Nature* 1994;367(6462):463-7.
15. Barbaro NR, Foss JD, Kryshtal DO, Tsyba N, Kumaresan S, Xiao L, et al. Dendritic cell amiloride-sensitive channels mediate sodium-induced inflammation and hypertension. *Cell Reports* 2017;21(4):1009-20.
16. Salih M, Gautschi I, van Bemmelen MX, Di Benedetto M, Brooks AS, Lugtenberg D, et al. A missense mutation in the extracellular domain of alphaENaC causes Liddle syndrome. *Journal of the American Society of Nephrology* 2017;28(11):3291-9.
17. Freercks R, Meldau S, Jones E, Ensor J, Weimers-Willard C, Rayner B. Liddle's syndrome in an African male due to a novel frameshift mutation in the beta-subunit of the epithelial sodium channel gene. *Cardiovascular Journal of Africa* 2017;28(4):e4-e6.
18. Su YR, Rutkowski MP, Klanke CA, Wu X, Cui Y, Pun RY, et al. A novel variant of the beta-subunit of the amiloride-sensitive sodium channel in African Americans. *Journal of the American Society of Nephrology* 1996;7(12):2543-9.
19. Cui Y, Su YR, Rutkowski M, Reif M, Menon AG, Pun RY. Loss of protein kinase C inhibition in the beta-T594M variant of the amiloride-sensitive Na<sup>+</sup> channel. *Proceedings of the*

*National Academy of Sciences of the United States of America* 1997;94(18):9962-6

20. Gamil S, Erdmann J, Abdalrahman IB, Mohamed AO. Association of NOS3 gene polymorphisms with essential hypertension in Sudanese patients: a case control study. *BMC Med Genet* 2017;18(1):128.

21. Poulter NR, Prabhakaran D, Caulfield M. Hypertension. *Lancet* 2015;386(9995):801-12.

22. Sherif SM, Ahmed M-EK, Homeida MM. Prevalence of hypertension in an urban community in Sudan. *Kharoum Medical Journal* 2008;1(2):72-4.

23. Bookman EB, McAllister K, Gillanders E, Wanke K, Balshaw D, Rutter J, et al. Gene-environment interplay in common complex diseases: forging an integrative model—recommendations from an NIH workshop. *Genetic Epidemiology* 2011;35(4):217-25.

24. Nkeh B, Samani NJ, Badenhorst D, Libhaber E, Sareli P, Norton GR, et al. T594M variant of the epithelial sodium channel beta-subunit gene and hypertension in individuals of African ancestry in South Africa. *American Journal of Hypertension* 2003;16(10):847-52.

25. Gupta MD, Girish MP, Sikdar S, Ahuja R, Shah D, Kumar R, et al. beta-T594M epithelial sodium channel gene polymorphism and essential hypertension in individuals of Indo-Aryan ancestry in Northern India. *Indian Heart Journal* 2014;66(4):397-400.

26. Matsubara M, Ohkubo T, Michimata M, Hozawa A, Ishikawa K, Katsuya T, et al. Japanese individuals do not harbor the T594M mutation but do have the P592S mutation in the C-terminus of the beta-subunit of the epithelial sodium channel: the Ohasama study. *Journal of Hypertension* 2000;18(7):861-6.

27. Kamide K, Tanaka C, Takiuchi S, Miwa Y, Yoshii M, Horio T, et al. Six missense mutations of the epithelial sodium channel beta and gamma subunits in Japanese hypertensives. *Hypertens Res* 2004;27(5):333-8.

28. Dong YB, Zhu HD, Baker EH, Sagnella GA, MacGregor GA, Carter ND, et al. T594M and G442V polymorphisms of the sodium channel beta subunit and hypertension in a black population. *Journal of Human Hypertension* 2001;15(6):425-30.

29. Baker EH, Dong YB, Sagnella GA, Rothwell M, Onipinla AK, Markandu ND, et al. Association of hypertension with T594M mutation in beta subunit of epithelial sodium channels in black people resident in London. *Lancet* 1998;351(9113):1388-92.